Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 27, 2015 10:59 PM ET


Company Overview of AnaptysBio, Inc.

Company Overview

AnaptysBio, Inc., an antibody development company, engages in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology. It provides ANB019, an anti-interleukin-36 receptor antibody; and ANB020, a pro-inflammatory cytokine involved in activation of allergy, asthma, and other Th2-type disorders. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

10421 Pacific Center Court

Suite 200

San Diego, CA 92121

United States

Founded in 2005





Key Executives for AnaptysBio, Inc.

Chief Executive Officer, President and Director
Executive Chair
Age: 50
Age: 52
Chief Financial Officer
Age: 49
Chief Development Officer
Age: 58
Compensation as of Fiscal Year 2015.

AnaptysBio, Inc. Key Developments

AnaptysBio Appoints Robert E. Hoffman as Chief Financial Officer

AnaptysBio, Inc. announced the appointment of Robert E. Hoffman as Chief Financial Officer. Mr. Hoffman joins the company after serving as Chief Financial Officer of Arena Pharmaceuticals, Inc. and Polaris Group. Prior to joining AnaptysBio, Mr. Hoffman was employed by Arena Pharmaceuticals, Inc. where since 1997 he served various roles with increasing responsibility leading to Senior Vice President, Finance and Chief Financial Officer since June 2012. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc. and Kura Oncology, Inc. He also serves as a member of the Financial Accounting Standards Board's Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers.

AnaptysBio Announces Board Appointments

AnaptysBio, Inc. announced the appointment of Hollings Renton and John Schmid to its Board of Directors. Mr. Renton received a B.S. in Mathematics from Colorado State University and a M.B.A. from the University of Michigan. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015.

AnaptysBio, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015

AnaptysBio, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, Hamza Suria, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Sigma-Genosys LP United States
Eurand, Inc. United States
Innocrin Pharmaceuticals Inc. United States
XTuit Pharmaceuticals, Inc. United States
Caraloe Inc. United States

Recent Private Companies Transactions

Private Placement
July 13, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AnaptysBio, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at